Leelamine (hydrochloride)

Leelamine hydrochloride is a tricyclic diterpene molecule that is extracted from the bark of pine trees[1]. Leelamine hydrochloride is a cannabinoid receptor type 1 (CB1) agonist and a inhibitor of SREBP1-regulated fatty acid/lipid synthesis in prostate cancer cells that is not affected by androgen receptor status. Leelamine hydrochloride suppresses transcriptional activity of androgen receptor, which is known to regulate fatty acid synthesis[2,3].

Product Specifications

CAS Number

[16496-99-4]

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

Androgen Receptor; Cannabinoid Receptor; Fatty Acid Synthase (FASN)

Type

Natural Products

Related Pathways

GPCR/G Protein; Metabolic Enzyme/Protease; Neuronal Signaling; Vitamin D Related/Nuclear Receptor

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Cancer; Endocrinology

Assay Protocol

https://www.medchemexpress.com/leelamine-hydrochloride.html

Purity

98.10

Solubility

DMSO : 25 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

NC[C@]1(C)CCC[C@]2(C)C3=C(CC[C@@]12[H])C=C(C(C)C)C=C3.Cl

Molecular Formula

C20H32ClN

Molecular Weight

321.93

Precautions

H315, H319, H335

References & Citations

[1]Kuzu OF, et al. Leelamine mediates cancer cell death through inhibition of intracellular cholesterol transport. Mol Cancer Ther. 2014 Jul;13 (7) :1690-703.|[2]A.O. Ibegbu, et al. Therapeutic Potentials and uses of Cannabinoid Agonists in Health and Disease Conditions. British Journal of Pharmacology and Toxicology 3 (2) : 76-88, 2012|[3]Singh KB, et al. Leelamine is a Novel Lipogenesis Inhibitor in Prostate Cancer Cells In Vitro and In Vivo. Mol Cancer Ther. 2019 Aug 8.